揭開腫瘤免疫療法面紗：淺談腫瘤免疫治療的美麗與哀愁

Uncovering the Veil of Tumor Immunotherapy: From Effect to Side Effect

10.6880/TJON.202112_21(2).01

張維容(Wei-Jung Chang)；陳幼貴(Yu-Kuei Chen)；陳怡君(I-Chun Chen)

免疫檢查點抑制劑 ； 不良反應 ； 癌症免疫療法 ； immune checkpoint inhibitor ； adverse events ； cancer immunotherapy

腫瘤護理雜誌

21卷2期（2021 / 12 / 01）

5 - 12

繁體中文

癌症免疫療法，尤其是免疫檢查點抑制劑，為新世代的治療，本文章由美國腫瘤學會（American Society of Clinical Oncology, ASCO）及歐洲腫瘤學會（European Society for Medical Oncology, ESMO）指引彙整出免疫檢查點抑制劑所引發的相關不良反應，包含皮膚、內分泌、肝臟、腸胃道、肺部及少數罕見症狀及臨床處理方式，讓第一線醫療照護者能早期發現徵象和評估，及早介入處理，提升病人臨床照護品質。

Cancer immunotherapy, especially immune checkpoint inhibitor, is a new generation of treatment. This article provides a summary of guidelines on immune related adverse events from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). We will cover the adverse events related to immune checkpoint inhibitor, such as toxicities on skin, endocrine, liver, gastrointestinal tract, and respiratory tract, as well as rare clinical presentations and their managements. This will help the frontline caregivers to early identify symptoms, to early intervene, and to improve the patient care quality.

1. Abbott, M.,Ustoyev, Y.(2019).Cancer and the immune system: The history and background of immunotherapy.Seminars in Oncology Nursing,35(5),150923.
2. Blidner, A. G.,Choi, J.,Cooksley, T.,Dougan, M.,Glezerman, I.,Ginex, P.,Girotra, M.,Gupta, D.,Johnson, D.,Shannon, V. R.,Suarez-Almazor, M.,Rapoport, B. L.,Anderson, R.(2020).Cancer immunotherapy-related adverse events: Causes and challenges.Support Care Cancer,28(12),6111-6117.
3. Haanen, J. B. A. G.,Carbonnel, F.,Robert, C.,Kerr, K. M.,Peters, S.,Larkin, J.,Jordan, K.(2017).Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Annals of Oncology,28,119-142.
4. Lipson, E. J.,Drake, C. G.(2011).Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.Clinical Cancer Research,17(22),6958-6962.
5. Tan, S.,Li, D.,Zhu, X.(2020).Cancer immunotherapy: Pros, cons and beyond.Biomedicine & Pharmacotherapy,124,109821.
6. Twomey, J. D.,Zhang, B.(2021).Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.An official journal of the American of Pharmaceutical Scientists,23(2),1-11.